Last reviewed · How we verify
Keveyis (DICHLORPHENAMIDE)
Keveyis works by inhibiting the enzyme carbonic anhydrase, which is involved in the production of aqueous humor in the eye.
Keveyis (Dichlorphenamide) is a small molecule carbonic anhydrase inhibitor developed by an unspecified original developer and currently owned by Xeris. It targets carbonic anhydrase 1 to treat various forms of glaucoma, including angle-closure, open-angle, and secondary glaucoma. Approved by the FDA in 1958, Keveyis is an off-patent medication with multiple generic manufacturers. As a carbonic anhydrase inhibitor, it works by reducing the production of aqueous humor in the eye, thereby lowering intraocular pressure. Keveyis is a valuable treatment option for patients with glaucoma, but its commercial status and pharmacokinetic properties are not well-documented.
At a glance
| Generic name | DICHLORPHENAMIDE |
|---|---|
| Sponsor | Xeris |
| Drug class | Carbonic Anhydrase Inhibitor [EPC] |
| Target | Carbonic anhydrase 1 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
| First approval | 1958 |
Mechanism of action
Dichlorphenamide is carbonic anhydrase inhibitor. However, the precise mechanism by which dichlorphenamide exerts its therapeutic effects in patients with primary periodic paralysis is unknown.
Approved indications
- Angle-closure glaucoma
- Open-angle glaucoma
- Secondary glaucoma
Common side effects
- Paresthesia
- Cognitive disorder
- Dysgeusia
- Confusional state
- Headache
- Diarrhea
- Arthralgia
- Rash
- Pruritus
- Dizziness
- Lethargy
- Hypoesthesia
Key clinical trials
- Hyper- and Hypokalemic Periodic Paralysis Study (PHASE3)
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Keveyis CI brief — competitive landscape report
- Keveyis updates RSS · CI watch RSS